• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

9.390 +0.270 (+2.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 678,090
Open 9.010
Bid (Size) 8.800 (200)
Ask (Size) 9.480 (200)
Prev. Close 9.120
Today's Range 8.937 - 9.460
52wk Range 6.890 - 16.19
Shares Outstanding 43,466,186
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
April 14, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 13, 2026
From Schall Law
Via GlobeNewswire

Performance

YTD
-30.8%
-30.8%
1 Month
+10.1%
+10.1%
3 Month
-12.9%
-12.9%
6 Month
-21.7%
-21.7%
1 Year
-9.7%
-9.7%

More News

Read More
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 09, 2026
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
April 07, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 06, 2026
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
April 05, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
April 04, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
April 03, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
April 02, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 02, 2026
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
March 31, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 30, 2026
From Schall Law
Via GlobeNewswire
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
March 26, 2026
Via Finterra
Topics Economy Initial Public Offering
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
March 24, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP
March 24, 2026
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
March 24, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 23, 2026
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
March 20, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
March 19, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action
March 19, 2026
From Robbins LLP
Via Business Wire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 19, 2026
From Schall Law
Via GlobeNewswire
News headline image
RGNX DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
March 19, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
March 17, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Stephen Pakola Oversaw RGX-111 Safety Claims That Cost RGNX Investors Millions: Levi & Korsinsky, LLP
March 17, 2026
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
March 17, 2026
From The Rosen Law Firm PA
Via GlobeNewswire

Frequently Asked Questions

Is REGENXBIO Inc. - Common Stock publicly traded?
Yes, REGENXBIO Inc. - Common Stock is publicly traded.
What exchange does REGENXBIO Inc. - Common Stock trade on?
REGENXBIO Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for REGENXBIO Inc. - Common Stock?
The ticker symbol for REGENXBIO Inc. - Common Stock is RGNX on the Nasdaq Stock Market
What is the current price of REGENXBIO Inc. - Common Stock?
The current price of REGENXBIO Inc. - Common Stock is 9.390
When was REGENXBIO Inc. - Common Stock last traded?
The last trade of REGENXBIO Inc. - Common Stock was at 05/04/26 04:00 PM ET
What is the market capitalization of REGENXBIO Inc. - Common Stock?
The market capitalization of REGENXBIO Inc. - Common Stock is 408.15M
How many shares of REGENXBIO Inc. - Common Stock are outstanding?
REGENXBIO Inc. - Common Stock has 408M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap